Lead Product(s) : Monomethyl Auristatin E
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : MBRC-101 (monomethyl auristatin E)is a novel, targeted ADC which targets the EphA5 receptor tyrosine kinase. It is under phase 1 clinical development for the treatment of multiple solid tumor cancers, including breast, non-small cell lung and other solid...
Brand Name : MBRC-101
Molecule Type : Large molecule
Upfront Cash : Not Applicable
December 19, 2023
Lead Product(s) : Monomethyl Auristatin E
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
Reset All
